Yuanta Investment
VC Fund
Seoul, South Korea
Yuanta Investment is a VC fund in Seoul focused on Biotechnology and Pharmaceutical. A star of private equity market grow up your companies and ascend your potential.
- Total investments:
- 62
- Last investment:
- Lead investor:
- 10%
- Fund size:
- $115M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Yuanta Investment invests in
Stages Yuanta Investment invests in
Countries Yuanta Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $5.6M–$57M
- Series B
- $3.7M–$44M
- Series C
- $12M–$45M
Investment Focus
Industry
- Biotechnology 17 (27%)
- Pharmaceutical 13 (21%)
- Medical 10 (16%)
- Health Care 8 (13%)
- Information Technology 8 (13%)
Stage
- Series B 24 (39%)
- Series A 13 (21%)
- Series C 12 (19%)
- Venture - Series Unknown 4 (6%)
- Seed 3 (5%)
Country
- South Korea 48 (77%)
- United States 3 (5%)
- Taiwan 1 (2%)
- Vietnam 1 (2%)
- Indonesia 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
KiSuk Yang
Vice Chairman
|
Vice Chairman | Total investments: 0 | Find email | |
|
SangWoon Hwang
CEO
|
CEO | Total investments: 1 | Find email | |
Park Sang-hyun
Director
|
Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| HITS is a biotech company that creates digital solutions to accelerate drug development and introduce a new drug discovery paradigm. The company creates a cloud-based drug development platform that connects AI models with docking and molecular dynamics. | $13.5M / Series B / Sep 28, 2026 | ||
| Nexcera provides innovative and sustainable medical solutions. | $16.2M / Series B / Sep 28, 2026 | ||
| ArcGen Bioscience is a biopharmaceutical development company focused on researching, developing, and advancing innovative therapeutic solutions to address unmet medical needs through cutting-edge biotechnology and drug development. | $6.7M / Series A / Jul 13, 2026 | ||
| MOAIS develops a smartphone AI solution that analyzes golf swing problem and offers a lesson solution. It is an on-device AI optimized for smart phones, has a video pose estimation, video segmentation, video classification, video object detection, and image processing of golf swing video. | $3.7M / Series B / Apr 30, 2026 | ||
| XYZ is an retail-tech startup that develops AI-based service robots and automation systems designed for use in commercial and everyday environments. The company builds robotic technologies that integrate hardware, software, and digital interfaces to automate tasks in areas such as food preparation, retail operations, and building services. Itssolutions combine robotics, artificial intelligence, and connected platforms to support unmanned or semi-automated service experiences within physical spaces. The company offers robotic systems that perform tasks such as automated beverage preparation, self-service food production, and customer interaction within retail or hospitality environments. These systems can integrate with mobile ordering, digital payment, and pickup workflows, enabling automated service processes from ordering to product delivery. The robots are designed to operate continuously while managing repetitive operational tasks typically performed by human staff.XYZ also develops building-level automation solutions that use delivery robots capable of navigating multiple floors and indoor spaces. Through a robot building solution platform, the company connects robots with building infrastructure and digital management systems to enable services such as in-building delivery and automated logistics. These systems allow operators to manage robots and service workflows across large indoor facilities. | $8.7M / Series B / Mar 09, 2026 | ||
| GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. Thecompany's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases. | $60M / Series B / Feb 25, 2026 | ||
| Galux provides molecular design technology focusing on discovering and developing novel drugs for incurable and rare diseases using its AI-based drug design platform technologies. | $29M / Series B / Feb 09, 2026 | ||
| MediMabBio platform uses systems biology combined with sophisticated immunological solutions to identify significantly improving immuno-oncology drugs that can actively target a range of solid tumors. The antibody discovery I-O platform brings the advantages of rational drug design to large molecule therapeutic development. | $17.8M / Series B / Oct 24, 2025 | ||
| Newracle Genetics is a bio venture company that develops gene therapy products for neurological diseases. | $18.8M / Series C / Sep 08, 2025 | ||
| Nex Eye is an innovative biotechnology firm that offers revolutionary immunotherapy solutions for individuals battling cancer. The company addresses the fundamental reasons behind the failure of immunotherapy, which are influenced by the biology of cancer itself. Utilizing its ON-SMRT® platform based on actual patient data and resistant cancermodels, Nex Eye identifies new immune-evasion targets such as ONCOKINE®. By transforming the approach to tackling immune resistance, the firm is pioneering a new era in cancer therapy by revitalizing the capabilities of the immune system. | $44.2M / Series B / Aug 13, 2025 | ||
| See all 62 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Yuanta Investment invest in?
Yuanta Investment invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series B and Series A stage. Most of the 62 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Yuanta Investment's check size?
Yuanta Investment typically joins rounds of $5.6M–$57M at Series A, $3.7M–$44M at Series B and $12M–$45M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Yuanta Investment participates in.
How do I contact Yuanta Investment?
Public channels for Yuanta Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Yuanta Investment?
The team at Yuanta Investment includes KiSuk Yang (Vice Chairman), SangWoon Hwang (CEO) and Park Sang-hyun (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
